New drug combo trial offers hope for Tough-to-Treat sarcoma
NCT ID NCT07156643
Summary
This study is testing whether a new combination of drugs works better for people with advanced soft tissue sarcoma that cannot be removed by surgery. About 46 participants will receive a targeted therapy drug (anlotinib) plus an immunotherapy drug (bempegaldesleukin) along with standard chemotherapy and radiation. The main goal is to see if this combination can shrink tumors and control the disease safely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
Nanjing, China
Contact
Conditions
Explore the condition pages connected to this study.